核苷（酸）类似物治疗慢性乙型肝炎安全性评价

doi:10.3969/j.issn.1672-5069.2015.05.031

Abstract

Abstract: The aim of antiviral therapy in patients with chronic hepatitis B is for a long-term to restrain or eliminate hepatitis B virus. Although the nucleos（t）ide analogues have excellent antiviral efficacy，but the therapy has the risk of rhabdomyolysis，lactic acidosis，nephrotoxicity and Fanconi syndrome. These adverse reactions are related to NAs -related mitochondrial toxicity. In this review，the safety of NAs in the treatment of patients with chronic hepatitis B will be discussed.

Key words: Hepatitis B, Nucleos（t）ide analogues, Rhabdomyolysis, Lactic acidosis, Nephrotoxicity, Fanconi syndrome

Zhou Pei，Zhang Haiyue， Gong Zuojiong. Side effects of nucleos （t） ide analogues in the treatment of patients with chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(5): 554-557.

References

[1] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志，2011，14（2）：81-89.
[2] Janice L，Zimmerman MD，Michael C，et al. Rhabdomyolysis. Chest，2013，144（3）：1058-1065.
[3] Khan FY. Rhabdomyolysi：a review of the literature. Neth J Med，2009，67（9）：272-283.
[4] 姚光弼，崔振宇，姚集鲁，等. 国产拉米夫定治疗2200例慢性乙型肝炎的Ⅳ期临床试验. 中华肝脏病杂志，2003，15（2）：40-45.
[5] 姚光弼，王宝恩，崔振宇，等. 拉米夫定治疗慢性乙型肝炎三年疗效观察.中华内科杂志，2003，22（6）：382-387.
[6] Lai CL，Gane E，Liaw YF，et a. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med，2007，357（25）：2576-2588.
[7] 孙梅影，漆学良，丁卫江，等. 拉米夫定致横纹肌溶解症1例. 山东医药，2013，53（20）：99-100.
[8] 国家食品药品监督管理局.警惕治疗乙型肝炎的核苷类抗病毒药替比夫定和拉米夫定的横纹肌溶解症.中国社区医生，2010，32（8）：8.
[9] Baharin J，Sahari NS，Lim SM.Rhabdomyolysis due to lamivudine administration in acute viral hepatitis B infection：a case report from Malaysia. Electron Physician，2014，6（3）：863-867.
[10] Mendila M，Walter GF，Stoll M，et al.Rhabdomyolysis in antiretroviral therapy with lamivudin.Dtsch Med Wochenschr，1997，122（33）：1003-1006.
[11] Adani GL，Baccarani U，Risaliti A，et al. Rhabdomyolysis due to lamivudine administration in a liver transplant rrecipient. Am J Transplantat，2005，5（3）：634-634.
[12] Fung J，Seto WK，Lai CL，et al. Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. J Gastroenterol Hepatol，2014，29（3）：428-434.
[13] Tanaka M，Suzuki F，Seko Y，et al. Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B. J Gastroenterol，2014，49（3）：470-80.
[14] Zhu LN，Mou LJ，Hu Y，et al. Fanconi syndrome caused by low-dose adefovir dipivoxil. Saudi Med J，2014，35（3）：309-313.
[15] Hall AM，Bass P，Unwin RJ. Drug-induced renal Fanconi syndrome. QJM，2014，107（4）：261-269.
[16] 刘秀坤，董乃清，严寓均，等. 46例阿德福韦酯致低血磷性骨软化症回顾性分析. 中国医院用药评价与分析，2014，14（2）：162-165.
[17] 王晓今，付青春，藏祖胜，等. 表现为范可尼综合征的阿德福韦酯相关慢性肾脏病15例分析. 肝脏，2014，19（7）：475-478.
[18] 李晓静，蒋玲，张燕燕，等.阿德福韦酯相关Fanconi综合征、低磷性骨软化症的临床分析.中华内分泌代谢杂志，2014，30（1）：47-49.
[19] 王霞，郑慧，章振林.阿德福韦酯致低血磷性骨软化症二例诊治分析. 中国全科医学，2013，16（5）：1755-1758.
[20] 李玲，董光富，张晓，等.阿德福韦酯致Fanconi综合征和低磷性骨软化症并进行性肌无力1例.南方科技大学学报，2011，31（11）：1956-1958.
[21] Wang BF，Wang Y，Wang BY，et al. Osteomalacia and Fanconi’s syndrome caused by long-term low-dose adefovir dipivoxil. J Clin Pharm Ther，2015，40（3）：345-348.
[22] Terasaka T，Ueta E，Ebara H，et al.Long-term observation of osteomalacia caused by adefovir-induced Fanconi's syndrome. Acta Med Okayama，2014，68（1）：53-56.
[23] Xu LJ，Jiang Y，Liao RX，et al. Low-dose adefovir dipivoxil may induce Fanconi syndrome：clinical characteristics and long-term follow-up for Chinese patients. Antivir Ther，2015，20（3）：1-15.
[24] Zhu LN，Mou LJ，Hu Y，et al. Fanconi syndrome caused by low-dose adefovir dipivoxil.Saudi Med J，2014，35（3）：309-313.
[25] 巫协宁.抗乙肝病毒核苷类似物的不良反应及其发生机制与防治. 胃肠病学和肝病学杂志，2011，20（5）：477-479.
[26] Lang CM，Bojunga J，Hofmann WP，et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function.Hepatology，2009，50（6）：2001-2006.
[27] Marzano A，Marengo A，Marietti M，et al. Lactic acidosis during entecavir treatment in decompensated hepatitis B virus-related cirrhosis. Dig Liver Dis，2011，43（12）：1027-1028.
[28] 莫国生，蔡永静，吴旭光，等. 恩替卡韦、利奈唑胺致乳酸性酸中毒死亡一例. 中华传染病杂志，2012，30（8）：483.
[29] 刘雪莲，杨见权，冯淑芬. 恩替卡韦引起乳酸酸中毒一例. 暨南大学学报（自然科学与医学版），2013，34（4）：445-446.
[30] 毛海鹰，康涛，邱邦东，等. 乙型肝炎肝硬化失代偿期应用恩替卡韦并发乳酸酸中毒1例. 中国医院药学杂志，2013，33（15）：1297-1298.
[31] Zhang X，Liu L，Zhang M，et al. The efficacy and safety of entecavir in patients with chronic hepatitis B- associated liver failure：a meta-analysis.Ann Hepatol，2015，14（2）：150-160.
[32] Jiang H，Wang J，Zhao W.Lamivudine versus telbivudine in the treatment of chronic hepatitis B：a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis，2013，32（1）：11-18.
[33] 任江波，王宇，李红艺，等. 替比夫定治疗慢性乙型肝炎期间肌酸激酶升高的观察与分析. 中华肝脏病杂志，2012，20（9）：641-643.
[34] Yu S，Zhou Q，Zhao XM，et al. Comparison of the antiviral effects of different nucleos（t）ide analogues in chinese patients with chronic hepatitis B：A head-to-head study. Saudi J Gastroenterol，2014，20（6）：350-355.
[35] Hou J，Yin YK，Xu D，et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B：Results at 1 year of a randomized，double-blind trial.Hepatology，2008，47（2）：447-454.
[36] Piccolo P，Lenci I，di Paolo D，et al. A randomized controlled trial of sequential pegylated interferon-alpha and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther，2013，18（1）：57-64.
[37] Mateo L，Holgado S，Mari?oso ML，et al. Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients. Clin Rheumatol，2014，45（2）：191-192.
[38] Samarkos M，Theofanis V，Eliadi I ，et al. Tenofovir-associated Fanconi syndrome in a patient with chronic hepatitis B. J Gastrointestin Liver Dis，2014，23（3）：342.
[39] Tien C，Xu JJ，Chan LS，et al. Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling. Dig Dis Sci，2014，59 （10）：128-135.
[40] Herlitz LC，Mohan S，Stokes MB，et al. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical，pathological，and mitochondrial abnormalities. Kidney Int，2010，78（11）：1171-1177.

Side effects of nucleos （t） ide analogues in the treatment of patients with chronic hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[8]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[9]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[10]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[11]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[12]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[13]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[14]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[15]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.